Kiora Pharmaceuticals to Provide 2022 Business Outlook at the H.C. Wainwright Bioconnect Virtual ConferenceNewsfile Corp • 01/05/22
Kiora Pharmaceuticals Appoints David Hollander, MD, MBA, to its Board of DirectorsNewsfile Corp • 12/15/21
Kiora Reports KIO-101 is Safe and Tolerable; Topline Data Supports Advancing KIO-101 to a Phase 2 Study in Patients with Dry Eye DiseaseNewsfile Corp • 12/14/21
Kiora Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 11/15/21
EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company's Sharpened Clinical Development StrategyGlobeNewsWire • 11/08/21